You are here: Industry Insights > Ocular Therapeutix

News List

Ocular Therapeutix announces first patient dosed in phase 1 clinical trial of OTX-CSI to treat dry e pharmaceutical-business-review
May 15, 2020
Ocular Therapeutix, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye.
Ocular Therapeutix Prices $37.5 Million Subordinated Convertible Debt Financing .firstwordpharma
February 24, 2019
The notes will be senior unsecured subordinated obligations of the Company and will mature on March 1, 2026, unless earlier converted, repurchased or redeemed in accordance with their terms
Ocular Therapeutix Announces Completion of Debt Refinancing biospectrumasia
January 02, 2019
The company enters into a $25.0 Million Term Loan with MidCap Financial and Silicon Valley Bank. The 5-year term loan facility allows for an expansion of the Company’s prior $18 million credit facility to $25.0 million, all of which was drawn at closing.
Ocular Therapeutix crosses finish line with eye treatment after running down production problems fiercepharma
December 05, 2018
After twice being sidelined by manufacturing-related CRLs, Ocular Therapeutix got FDA approval on Monday for its first eye drug.
FDA Approves Dextenza drugs
December 04, 2018
FDA Approves Dextenza (dexamethasone ophthalmic insert) for the Treatment of Ocular Pain Following Ophthalmic Surgery.Ocular Therapeutix™, Inc. a biopharmaceutical company focused .......
Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for Dextenza americanpharmaceuticalreview
July 24, 2018
Ocular Therapeutix has received acknowledgement from the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for Dextenza has been received.